Back to results
US 2007/0179152 A1Published application
Combination therapy for the treatment of neoplasms
OwnerMargaret Lee, M. Nichols +2inventors
InventorsMargaret Lee, M. Nichols, Amy Wilson, Grant Zimmermann
Life of this patent
Estimating the term…
Abstract
The invention features compositions, methods, and kits for the treatment of neoplasms
Claims26
A pharmaceutical composition, comprising an antiarrhythmic agent;
- a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein X is CH2 or N;
- Z is CH2 or O;
- Ar is selected from the group consisting of phenyl, thienyl, halothienyl, and substituted phenyl, said substituted phenyl having from 1 to 3 substituents, each independently selected from the group consisting of halo, C1-C6 linear or branched alkyl, linear or branched C1-C6 alkoxy, and trifluoromethyl;
- and Y is a group having the formula:
- wherein R1 is selected from the group consisting of C1-C6 linear or branched alkyl having 0 or 1 hydroxyl substituents and C1-C6 linear or branched alkaryl, and R2 is selected from the group consisting of H, linear or branched C1-C6 alkyl, and C1-C6 alkaryl, wherein said aryl group is a phenyl ring having from 0 to 3 substituents, each independently selected from the group consisting of halo, C1-C6 linear or branched alkyl, linear or branched C1-C6 alkoxy, and trifluoromethyl;
- and a pharmaceutically acceptable carrier.
4 more elements
A method of treating a neoplasm in a patient, said method comprising administering to said patient an antiarrhythmic agent and a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein X is CH2 or N;
- Z is CH2 or O;
- Ar is selected from the group consisting of phenyl, thienyl, halothienyl, and substituted phenyl, said substituted phenyl having from 1 to 3 substituents, each independently selected from the group consisting of halo, C1-C6 linear or branched alkyl, linear or branched C1-C6 alkoxy, and trifluoromethyl;
- and Y is a group having the formula:
- wherein R1 is selected from the group consisting of C1-C6 linear or branched alkyl having 0 or 1 hydroxyl substituents and C1-C6 linear or branched alkaryl, and R2 is selected from the group consisting of H, linear or branched C1-C6 alkyl, and C1-C6 alkaryl, wherein said aryl group is a phenyl ring having from 0 to 3 substituents, each independently selected from the group consisting of halo, C1-C6 linear or branched alkyl, linear or branched C1-C6 alkoxy, and trifluoromethyl, wherein said antiarrhythmic agent and said compound of formula (I) are administered in amounts that together are effective to treat said neoplasm.
2 more elements
A kit, comprising:
- (i) a composition comprising an antiarrhythmic agent and a compound of formula (I), or a pharmaceutically acceptable salt thereof;
- and
- (ii) instructions for administering said composition to a patient diagnosed with or at risk of developing a neoplasm.
A kit, comprising:
- (i) an antiarrhythmic agent;
- (ii) a compound of formula (I), or a pharmaceutically acceptable salt thereof;
- and
- (iii) instructions for administering said antiarrhythmic agent and said compound of formula (I) to a patient diagnosed with or at risk of developing a neoplasm.
1 more element
A kit, comprising:
- (i) an antiarrhythmic agent;
- and
- (ii) instructions for administering said antiarrhythmic agent and a compound of formula (I), or a pharmaceutically acceptable salt thereof, to a patient diagnosed with or at risk of developing a neoplasm.
A kit, comprising:
- (i) a compound of formula (I), or a pharmaceutically acceptable salt thereof;
- and
- (iii) instructions for administering said compound of formula (I) and an antiarrhythmic agent to a patient diagnosed with or at risk of developing a neoplasm.
Dependencies are inferred from the claim text.